

## Correction to: Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?

This is a correction to: Ethan Chen, Alexander L Ling, David A Reardon, E Antonio Chiocca, Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?, *Neuro-Oncology*, 2023, noad211, <https://doi.org/10.1093/neuonc/noad211>

In the originally published version of this manuscript, there is a factual mistake in the sentence:

In this manuscript, the data were reanalyzed and now the DCVax-L group exhibited a mOS of 19.3 months, almost 4 months lower than the one reported previously

The correct version should state:

In this manuscript, the data were reanalyzed and now the DCVax-L group exhibited a mOS of 19.3 months from randomization and 22.4 months from surgery.

This error has been corrected online.